Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Renal Cell 73Neoplasm Metastasis 30Kidney Neoplasms 26Neoplasms 19Breast Neoplasms 14Prostatic Neoplasms 12Urinary Bladder Neoplasms 10Melanoma 9Gastrointestinal Stromal Tumors 9Brain Neoplasms 9Glioblastoma 8Sarcoma 7Carcinoma, Non-Small-Cell Lung 7Liver Neoplasms 6Carcinoma, Hepatocellular 6Recurrence 5Pancreatic Neoplasms 5Ovarian Neoplasms 5Esophageal Neoplasms 5Colorectal Neoplasms 5Thyroid Neoplasms 4Solid Tumors 4Osteosarcoma 4Lung Neoplasms 4Leukemia, Myeloid, Acute 4Adenocarcinoma 4Uveal Melanoma 3Thymoma 3Stomach Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

Vorinostat 2pembrolizumab 1dactolisib 1Vinorelbine 1Sunitinib 1Oxaliplatin 1Levoleucovorin 1Leucovorin 1Hydroxychloroquine 1Folfox protocol 1Fluorouracil 1Dasatinib 1Cetuximab 1Bevacizumab 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Malignant Solid Tumour × Sunitinib × Clear all
NCT01286896 2025-07-10

Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors

The Netherlands Cancer Institute

Phase 1 Completed
43 enrolled
Other solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡